Lung Cancer

Genomic Profiling in Lung Cancer and its application to help inform treatment for ALK+ NSCLC

Sponsored by Takeda Pharmaceuticals

While targeted therapies for ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) have improved outcomes and quality of life for patients, acquired resistance inevitably occurs in patients who initially respond to treatment.1 Molecular profiling at diagnosis and at progression can provide predictors of ongoing therapy response and help individualise patient management.2 The limbic spoke to medical ...

Already a member?

Login to keep reading.

© 2021 the limbic